Market Overview

A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump's Opioid Declaration

Share:
A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump's Opioid Declaration

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) spiked 46 percent Thursday when President Donald Trump declared a crackdown on opioid abuse.

“We’re going to be spending lots of money on coming up with a non-addictive solutions,” Trump said during a press conference.

The company develops opioid antagonists to treat substance abuse and addiction, including NARCAN Nasal Spray, the first and only Food and Drug Administration approved spray to reverse opioid overdoses.

Opiant also produces a heroin vaccine and a treatment for Cocaine Use Disorder, lending it deeper exposure to the government’s anti-drug campaign.

Trump’s commitment to combat substance abuse extends to both heroin and cocaine.

The new national circumstances will be a boon for a stock that, until July, never traded above $10. It had a strong run in the last quarter, hit an all-time high of $51.90, and now trades up 672 percent at a rate of $40.82.

Opiant closed Thursday's regular session at $40.15, up 35.6 percent on the day.

Related Links:

22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency

John Kapoor, Founder Of Insys, Indicted On Charges Of Bribing Doctors To Overprescribe Opioids

Posted-In: Donald Trump Opioid OpioidsNews Health Care Movers General Best of Benzinga

 

Related Articles (OPNT)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Vetr Upgrades First Solar As Company Posts Strong Q3

Intel Has Record EPS In Q3